Victory Capital Management’s Protara Therapeutics TARA Stock Holding History

Victory Capital Management’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,862	Closed	-$42K	–	3212
2020 Q1	$42K	Buy	+1,862	New	+$54.2K	﹤0.01%	2844
2019 Q4	–	Sell	-57	Closed	-$1K	–	3220
2019 Q3	$1K	Buy	+57	New	+$816	﹤0.01%	3719

Other funds holding TARA

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management's TARA Position: Q2 2020 in Review

Victory Capital Management sold out of Protara Therapeutics (TARA) in Q2 2020, closing a stake of 1,862 shares — an estimated $42K sold.

Victory Capital Management first reported a position in TARA in Q3 2019 and held it in 2 quarters. The position peaked at $42K in Q1 2020. 33 funds tracked by Wall St. Rank hold TARA as of Q2 2020.

Victory Capital Management reported no remaining Protara Therapeutics position as of Q2 2020 after selling out during the quarter.
Victory Capital Management sold 1,862 Protara Therapeutics shares in Q2 2020, an estimated $42K.
Victory Capital Management first reported a position in Protara Therapeutics in Q3 2019 and held it in 2 quarters.
Victory Capital Management's Protara Therapeutics position peaked at $42K in Q1 2020.
33 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.